


PROspective Multicenter Imaging Study for Evaluation of Chest Pain

Evaluating a patient with chest pain? Which will you choose?



CTA?



Exercise ECG?



Stress nuclear?



Stress echo?

Please consider the PROMISE trial for patients meeting the following eligibility criteria.

inclusion criteria

- New or worsening chest pain or equivalent symptoms suspicious for clinically significant CAD
- No prior evaluation for this episode of symptoms
- **3.** Planned non-invasive testing for diagnosis
- **4.** Men age \ge 55 years and women age \ge 65, with or without risk factors
- **5.** If age in men 45–54 or women 50–64 years, must have increased probability of CAD due to either:
 - A. Diabetes requiring medical treatment OR
 - Peripheral arterial disease (≥ 50% peripheral arterial stenosis

exclusion criteria

- Diagnosed or suspected acute coronary syndrome requiring hospitalization or urgent or emergent testing; elevated troponin or CK-MB
- Hemodynamically or clinically unstable condition (systolic BP < 90 mm Hg, atrial or ventricular arrhythmias, or persistent resting chest pain felt to be ischemic despite adequate therapy)
- Known CAD with prior MI, PCI, CABG or any angiographic evidence of CAD
 ≥ 50% lesion in a major epicardial vessel
- **4.** Any invasive coronary angiography or non-invasive anatomic or functional CV test for detection of CAD, including CTA and exercise ECG, within previous 12 months

PROMISE is a prospective, phase 4, pragmatic, randomized trial of clinical effectiveness of imaging strategies, comparing the value of anatomic testing (coronary CT angiography [CTA]) to functional testing (exercise ECG, stress nuclear, stress echo).

treated medically or invasively **OR** cerebrovascular disease [stroke, documented ≥ 50% carotid stenosis treated medically or invasively])

OR

- **B.** At least 1 of the following cardiovascular risk factors:
 - Ongoing tobacco use
 - Hypertension
 - Abnormal ankle-brachial index < 0.9
 - Dyslipidemia
- 6. Serum creatinine ≤ 1.5 mg/dL within past 90 days
- 7. Negative urine/serum pregnancy test for female subjects of child-bearing potential

- 5. Known significant congenital, valvular (≥ moderate) or cardiomyopathic process (hypertrophic cardiomyopathy or reduced systolic left ventricular function [LVEF ≤ 40%]) which could explain cardiac symptoms
- **6.** Contraindication to undergoing a CTA, including but not limited to:
 - **a.** Allergy to iodinated contrast agent
 - b. Unable to receive beta blockers unless heart rate ≤ 65 bpm
 - c. Pregnancy
- 7. Life expectancy < 2 years
- 8. Unable to provide written informed consent or participate in long-term follow-up

To refer potential patients, please contact:

study coordinator

phone number

email address

For more information about the **PROMISE** study, please visit www.promisetrial.org